The Experts below are selected from a list of 477 Experts worldwide ranked by ideXlab platform
Jean-louis Saulnier - One of the best experts on this subject based on the ideXlab platform.
-
stability of Fludrocortisone Acetate solutions prepared from tablets and powder
European Journal of Pharmaceutics and Biopharmaceutics, 2003Co-Authors: Salvatore Cisternino, Joël Schlatter, Jean-louis SaulnierAbstract:To assess the stability of Fludrocortisone Acetate oral solutions prepared from tablets and powder at three temperatures over a 60-days period. Solutions of Fludrocortisone Acetate 40 microg/ml were prepared from commercially available 0.05-mg tablets and powder in ethanol 17% v/v. They stored in an amber glass prescription bottles at +4, +23 and +40 degrees C shielded from light. The concentrations of Fludrocortisone Acetate were determined in duplicate by high-performance liquid chromatography at 0, 1, 7, 14, 30, 50 and 60 days. The initial and final pH of solutions were compared. The recovery of Fludrocortisone Acetate from tablets was determined. The times (t(90)) needed for Fludrocortisone Acetate to fall to 90% of it's initial concentration were calculated by a linear regression analysis to allow the determination of the expired dates. The recovery of Fludrocortisone Acetate from tablets was 78 +/- 3%. The t(90) expressed with 95% confidence limits were 2 +/- 1 and 22 +/- 3 days for the solutions prepared from tablets and stored at +23 and +4 degrees C, respectively, whereas t(90) were 11 +/- 2 days and at least 60 days for the solutions prepared with the powder and stored at +23 and +4 degrees C, respectively. No color or odour changes were observed during the study period. The initial pH of the solutions prepared from tablets and powder were 7.7 and 6.9, respectively. No change of pH values was observed at the end of the 60 days. Significant degradation of Fludrocortisone Acetate occurred in formulations stored at +23 degrees C. Fludrocortisone Acetate 40 microg/ml solutions prepared from tablets and powder were stable 19 days and at least 60 days, respectively, when stored at +4 degrees C. The solution prepared from powder is the best in term of stability and final concentration which is independent on the Fludrocortisone Acetate recovery.
-
Stability of Fludrocortisone Acetate solutions prepared from tablets and powder
European Journal of Pharmaceutics and Biopharmaceutics, 2003Co-Authors: Salvatore Cisternino, Joël Schlatter, Jean-louis SaulnierAbstract:Abstract To assess the stability of Fludrocortisone Acetate oral solutions prepared from tablets and powder at three temperatures over a 60-days period. Solutions of Fludrocortisone Acetate 40 μg/ml were prepared from commercially available 0.05-mg tablets and powder in ethanol 17% v/v. They stored in an amber glass prescription bottles at +4, +23 and +40°C shielded from light. The concentrations of Fludrocortisone Acetate were determined in duplicate by high-performance liquid chromatography at 0, 1, 7, 14, 30, 50 and 60 days. The initial and final pH of solutions were compared. The recovery of Fludrocortisone Acetate from tablets was determined. The times (t90) needed for Fludrocortisone Acetate to fall to 90% of it's initial concentration were calculated by a linear regression analysis to allow the determination of the expired dates. The recovery of Fludrocortisone Acetate from tablets was 78±3%. The t90 expressed with 95% confidence limits were 2±1 and 22±3 days for the solutions prepared from tablets and stored at +23 and +4°C, respectively, whereas t90 were 11±2 days and at least 60 days for the solutions prepared with the powder and stored at +23 and +4°C, respectively. No color or odour changes were observed during the study period. The initial pH of the solutions prepared from tablets and powder were 7.7 and 6.9, respectively. No change of pH values was observed at the end of the 60 days. Significant degradation of Fludrocortisone Acetate occurred in formulations stored at +23°C. Fludrocortisone Acetate 40 μg/ml solutions prepared from tablets and powder were stable 19 days and at least 60 days, respectively, when stored at +4°C. The solution prepared from powder is the best in term of stability and final concentration which is independent on the Fludrocortisone Acetate recovery.
Salvatore Cisternino - One of the best experts on this subject based on the ideXlab platform.
-
stability of Fludrocortisone Acetate solutions prepared from tablets and powder
European Journal of Pharmaceutics and Biopharmaceutics, 2003Co-Authors: Salvatore Cisternino, Joël Schlatter, Jean-louis SaulnierAbstract:To assess the stability of Fludrocortisone Acetate oral solutions prepared from tablets and powder at three temperatures over a 60-days period. Solutions of Fludrocortisone Acetate 40 microg/ml were prepared from commercially available 0.05-mg tablets and powder in ethanol 17% v/v. They stored in an amber glass prescription bottles at +4, +23 and +40 degrees C shielded from light. The concentrations of Fludrocortisone Acetate were determined in duplicate by high-performance liquid chromatography at 0, 1, 7, 14, 30, 50 and 60 days. The initial and final pH of solutions were compared. The recovery of Fludrocortisone Acetate from tablets was determined. The times (t(90)) needed for Fludrocortisone Acetate to fall to 90% of it's initial concentration were calculated by a linear regression analysis to allow the determination of the expired dates. The recovery of Fludrocortisone Acetate from tablets was 78 +/- 3%. The t(90) expressed with 95% confidence limits were 2 +/- 1 and 22 +/- 3 days for the solutions prepared from tablets and stored at +23 and +4 degrees C, respectively, whereas t(90) were 11 +/- 2 days and at least 60 days for the solutions prepared with the powder and stored at +23 and +4 degrees C, respectively. No color or odour changes were observed during the study period. The initial pH of the solutions prepared from tablets and powder were 7.7 and 6.9, respectively. No change of pH values was observed at the end of the 60 days. Significant degradation of Fludrocortisone Acetate occurred in formulations stored at +23 degrees C. Fludrocortisone Acetate 40 microg/ml solutions prepared from tablets and powder were stable 19 days and at least 60 days, respectively, when stored at +4 degrees C. The solution prepared from powder is the best in term of stability and final concentration which is independent on the Fludrocortisone Acetate recovery.
-
Stability of Fludrocortisone Acetate solutions prepared from tablets and powder
European Journal of Pharmaceutics and Biopharmaceutics, 2003Co-Authors: Salvatore Cisternino, Joël Schlatter, Jean-louis SaulnierAbstract:Abstract To assess the stability of Fludrocortisone Acetate oral solutions prepared from tablets and powder at three temperatures over a 60-days period. Solutions of Fludrocortisone Acetate 40 μg/ml were prepared from commercially available 0.05-mg tablets and powder in ethanol 17% v/v. They stored in an amber glass prescription bottles at +4, +23 and +40°C shielded from light. The concentrations of Fludrocortisone Acetate were determined in duplicate by high-performance liquid chromatography at 0, 1, 7, 14, 30, 50 and 60 days. The initial and final pH of solutions were compared. The recovery of Fludrocortisone Acetate from tablets was determined. The times (t90) needed for Fludrocortisone Acetate to fall to 90% of it's initial concentration were calculated by a linear regression analysis to allow the determination of the expired dates. The recovery of Fludrocortisone Acetate from tablets was 78±3%. The t90 expressed with 95% confidence limits were 2±1 and 22±3 days for the solutions prepared from tablets and stored at +23 and +4°C, respectively, whereas t90 were 11±2 days and at least 60 days for the solutions prepared with the powder and stored at +23 and +4°C, respectively. No color or odour changes were observed during the study period. The initial pH of the solutions prepared from tablets and powder were 7.7 and 6.9, respectively. No change of pH values was observed at the end of the 60 days. Significant degradation of Fludrocortisone Acetate occurred in formulations stored at +23°C. Fludrocortisone Acetate 40 μg/ml solutions prepared from tablets and powder were stable 19 days and at least 60 days, respectively, when stored at +4°C. The solution prepared from powder is the best in term of stability and final concentration which is independent on the Fludrocortisone Acetate recovery.
Robert L Thunhorst - One of the best experts on this subject based on the ideXlab platform.
-
effects of Fludrocortisone on water and sodium intake of c57bl 6 mice
American Journal of Physiology-regulatory Integrative and Comparative Physiology, 2015Co-Authors: Ralph F Johnson, Terry G Beltz, Alan Kim Johnson, Robert L ThunhorstAbstract:Little is known about steroidal control of thirst- and salt-appetite behaviors of mice. The current study investigates effects of Fludrocortisone Acetate (FCA), a steroid with potent glucocorticoid and mineralocorticoid effects, on thirst- and salt-appetite responses of C57BL/6 mice. Treatment with FCA produced dose-dependent (5, 10, and 25 mg/kg) increases in both magnitude and duration of water and sodium intake. Chronic elevation of water and saline intake was achieved with daily injections of FCA. Daily injection of FCA, when only 0.9% saline was available, produced a remarkably rapid increase in saline intake. A single injection of FCA stimulated brisk diuresis and natriuresis in fluid-restricted animals. This work is the first to demonstrate copious water drinking by mice in response to FCA. The results are discussed in terms of the possibility that the renal effects of FCA promote increases in water and sodium turnover and thereby, increases in water and sodium ingestion.
-
Effects of Fludrocortisone on water and sodium intake of C57BL/6 mice
American journal of physiology. Regulatory integrative and comparative physiology, 2015Co-Authors: Ralph F Johnson, Terry G Beltz, Alan Kim Johnson, Robert L ThunhorstAbstract:Little is known about steroidal control of thirst- and salt-appetite behaviors of mice. The current study investigates effects of Fludrocortisone Acetate (FCA), a steroid with potent glucocorticoid and mineralocorticoid effects, on thirst- and salt-appetite responses of C57BL/6 mice. Treatment with FCA produced dose-dependent (5, 10, and 25 mg/kg) increases in both magnitude and duration of water and sodium intake. Chronic elevation of water and saline intake was achieved with daily injections of FCA. Daily injection of FCA, when only 0.9% saline was available, produced a remarkably rapid increase in saline intake. A single injection of FCA stimulated brisk diuresis and natriuresis in fluid-restricted animals. This work is the first to demonstrate copious water drinking by mice in response to FCA. The results are discussed in terms of the possibility that the renal effects of FCA promote increases in water and sodium turnover and thereby, increases in water and sodium ingestion.
Hyun Lee Kim - One of the best experts on this subject based on the ideXlab platform.
-
Original Article Effect of Fludrocortisone Acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis
2015Co-Authors: Dongmin Kim, Jong Hoon Chung, Sung Ho Yoon, Hyun Lee KimAbstract:Background. Hyperkalaemia is a commonly encoun-tered problem in dialysis patients with end-stage renal disease (ESRD). The aim of the present study was to assess the effect of Fludrocortisone Acetate (FCA) on reducing serum potassium levels in haemodialysis (HD) patients with hyperkalaemia. Methods. Prospectively, 21 HD patients with hyperka-laemia were enrolled in this study. Patients were divided into two groups, including FCA (0.1mg/d, n 13) administration or no treatment (control, n 8) for 10 months. No changes in dialysis or drug regimens were made during this period. Result. There were no significant differences in the baseline characteristics and biochemical parameters between the two groups (FCA therapy and control). At 10-months after FCA therapy, serum potassium levels were not significantly different between the treatment and control groups [median value (range): 5.2 (4.4–6.0) vs 5.8 (4.8–6.3)mEq/l, P 0.121]. However, using the Wilcoxon signed ranks test, serum potassium levels were significantly lower at the end of the 10 month time period after FCA therapy compared with serum potassium levels of the pre-treatment period [5.2 (4.4–6.0) vs 6.1 (5.3–6.8), P 0.01]. The biochemical values, including sodium, chloride, protein, albumin, blood nitrogen, creatinine, interdialytic weight change and blood pressure, did not show significant difference in comparisons between the two groups and pre-and post-FCA therapy period. Conclusions. FCA therapy appears to slightly decrease serum potassium value in hyperkalaemic HD patients. However, these results are insufficient to explain the effectiveness of FCA. Therefore, potentially large-scale studies with increased dose concentrations are needed to minimize the positive potassium balance in hyper-kalaemic HD patients
-
effect of Fludrocortisone Acetate on reducing serum potassium levels in patients with end stage renal disease undergoing haemodialysis
Nephrology Dialysis Transplantation, 2007Co-Authors: Dongmin Kim, Jong Hoon Chung, Sung Ho Yoon, Hyun Lee KimAbstract:Background. Hyperkalaemia is a commonly encountered problem in dialysis patients with end-stage renal disease (ESRD). The aim of the present study was to assess the effect of Fludrocortisone Acetate (FCA) on reducing serum potassium levels in haemodialysis (HD) patients with hyperkalaemia. Methods. Prospectively, 21 HD patients with hyperkalaemia were enrolled in this study. Patients were divided into two groups, including FCA (0.1 mg/d, n ¼ 13) administration or no treatment (control, n ¼ 8) for 10 months. No changes in dialysis or drug regimens were made during this period. Result. There were no significant differences in the baseline characteristics and biochemical parameters between the two groups (FCA therapy and control). At 10-months after FCA therapy, serum potassium levels were not significantly different between the treatment and control groups [median value (range): 5.2 (4.4–6.0) vs 5.8 (4.8–6.3) mEq/l, P ¼ 0.121]. However, using the Wilcoxon signed ranks test, serum potassium levels were significantly lower at the end of the 10 month time period after FCA therapy compared with serum potassium levels of the pre-treatment period [5.2 (4.4–6.0) vs 6.1 (5.3–6.8), P ¼ 0.01]. The biochemical values, including sodium, chloride, protein, albumin, blood nitrogen, creatinine, interdialytic weight change and blood pressure, did not show significant difference in comparisons between the two groups and pre-and post-FCA therapy period. Conclusions. FCA therapy appears to slightly decrease serum potassium value in hyperkalaemic HD patients. However, these results are insufficient to explain the effectiveness of FCA. Therefore, potentially large-scale studies with increased dose concentrations are needed to minimize the positive potassium balance in hyperkalaemic HD patients.
H S Kooistra - One of the best experts on this subject based on the ideXlab platform.
-
urinary aldosterone to creatinine ratio in cats before and after suppression with salt or Fludrocortisone Acetate
Journal of Veterinary Internal Medicine, 2008Co-Authors: S C Djajadiningratlaanen, S Galac, S E Cammelbeeck, K J C Van Laar, Peter Boer, H S KooistraAbstract:Background: The endocrine diagnosis of primary hyperaldosteronism in cats currently is based on an increased plasma aldosterone to renin ratio, which has several disadvantages for use in veterinary practice. Objectives: To establish a reference range for the urinary aldosterone to creatinine ratio (UACR) and to determine whether oral administration of either sodium chloride or Fludrocortisone Acetate is effective for use in a suppression test. Animals: Forty-two healthy cats from an animal shelter and 1 cat with primary hyperaldosteronism from a veterinary teaching hospital. Methods: Morning urine samples for determination of the basal UACR were collected from 42 healthy cats. For the suppression tests, urine samples for the UACR were collected after twice daily oral administration for 4 consecutive days of either sodium chloride, 0.25 g/kg body weight (n = 22) or Fludrocortisone Acetate, 0.05 mg/kg body weight (n = 15). Results: The median basal UACR was 7.2 × 10−9 (range, 1.8–52.3 × 10−9), with a calculated reference range of <46.5 × 10−9. Administration of sodium chloride resulted in adequate salt loading in 10 of 22 cats, but without significant reduction in the UACR. Administration of Fludrocortisone resulted in a significant decrease in the UACR (median, 78%; range, 44–97%; P < .001) in healthy cats. In the cat with an aldosterone-producing adrenocortical carcinoma, the basal UACR and the UACR after Fludrocortisone administration were 32 × 10−9 and 36 × 10−9, respectively. Conclusions and Clinical Importance: Using the UACR for an oral Fludrocortisone suppression test may be useful for the diagnosis of primary hyperaldosteronism in cats.
-
Urinary aldosterone to creatinine ratio in cats before and after suppression with salt or Fludrocortisone Acetate.
Journal of Veterinary Internal Medicine, 2008Co-Authors: S.c. Djajadiningrat-laanen, S Galac, S E Cammelbeeck, K J C Van Laar, Peter Boer, H S KooistraAbstract:Background: The endocrine diagnosis of primary hyperaldosteronism in cats currently is based on an increased plasma aldosterone to renin ratio, which has several disadvantages for use in veterinary practice. Objectives: To establish a reference range for the urinary aldosterone to creatinine ratio (UACR) and to determine whether oral administration of either sodium chloride or Fludrocortisone Acetate is effective for use in a suppression test. Animals: Forty-two healthy cats from an animal shelter and 1 cat with primary hyperaldosteronism from a veterinary teaching hospital. Methods: Morning urine samples for determination of the basal UACR were collected from 42 healthy cats. For the suppression tests, urine samples for the UACR were collected after twice daily oral administration for 4 consecutive days of either sodium chloride, 0.25 g/kg body weight (n = 22) or Fludrocortisone Acetate, 0.05 mg/kg body weight (n = 15). Results: The median basal UACR was 7.2 × 10−9 (range, 1.8–52.3 × 10−9), with a calculated reference range of